What is claimed is:

1. Use of Chidamide in the manufacture of a medicament for treating B-cell lymphoma, wherein the medicament is administered in combination with rituximab (R), cyclophosphamide (CTX), epirubicin (EPI), vincristine (VCR) and prednisone (Pred), in accordance with the administration methods in the following table:

Drug name	Dosage	Method of administration	Time of administration
R	375 mg/m^2	Intravenous bolus	Day 1
CTX	750 mg/m^2	Intravenous bolus	Day 2
EPI	70 mg/m^2	Intravenous bolus	Day 2
VCR	1.4 mg/m^2	Intravenous bolus	Day 2
Pred	60 mg/m^2	Oral	Days 2 to 6
Chidamide	20 mg/d	Oral	Days 1, 4, 8, 11
Duration of 1 course			21 days

.

2. The use according to claim 1, wherein the B-cell lymphoma is diffuse large B-cell lymphoma.

3. The use according to claim 2, wherein the diffuse large B-cell lymphoma is CD20 positive.

4. The use according to any one of claims 1-3, wherein the administration of Chidamide and rituximab (R), cyclophosphamide (CTX), epirubicin (EPI), vincristine (VCR) and prednisone (Pred) is repeated for 6 courses once every 21 days.

5. A pharmaceutical composition comprising Chidamide for the treatment of B-cell lymphoma, wherein the pharmaceutical composition is administered in combination with rituximab (R) cyclophosphamide (CTX), epirubicin (EPI), vincristine (VCR) and prednisone (Pred), in accordance with the administration methods in the following table:

Drug name	Dosage	Method of administration	Time of administration
R	375 mg/m^2	Intravenous bolus	Day 1
CTX	750 mg/m^2	Intravenous bolus	Day 2

EPI	70 mg/m^2	Intravenous bolus	Day 2
VCR	1.4 mg/m^2	Intravenous bolus	Day 2
Pred	60 mg/m^2	Oral	Days 2 to 6
Chidamide	20 mg/d	Oral	Days 1, 4, 8, 11
Duration of 1 course			21 days

.

6. The pharmaceutical composition according to claim 5, wherein the B-cell lymphoma is diffuse large B-cell lymphoma.

7. The pharmaceutical composition according to claim 6, wherein the diffuse large B-cell lymphoma is CD20 positive.

8. The pharmaceutical composition according to any one of claims 5-7, wherein the administration of Chidamide and rituximab (R), cyclophosphamide (CTX), epirubicin (EPI), vincristine (VCR) and prednisone (Pred) is repeated for 6 courses once every 21 days.